Polylactic Acid Sutures: Advanced Biodegradable Solutions For Surgical Wound Closure And Tissue Repair

Molecular Composition And Structural Characteristics Of Polylactic Acid Sutures

Polylactic acid sutures are fabricated from poly(L-lactic acid) (PLLA), poly(D,L-lactic acid), or their copolymers with glycolic acid, forming the poly(lactic-co-glycolic acid) (PLGA) family69. The stereochemical configuration profoundly influences material properties: PLLA exhibits semi-crystalline morphology with crystallinity ranging from 37% to 45%, yielding tensile strength between 50-70 MPa and elastic modulus of 2.7-4.8 GPa9. In contrast, the racemic poly(D,L-lactic acid) remains amorphous with lower modulus (1.9-2.4 GPa) but enhanced flexibility9. The glass transition temperature (Tg) of PLLA typically ranges from 55-65°C, while melting temperature (Tm) spans 170-180°C, enabling melt-processing via extrusion or electrospinning18.

Copolymerization with glycolic acid units modulates degradation rates and mechanical properties through disruption of crystalline domains. PLGA sutures with glycolide:lactide ratios of 90:10 degrade within 1-2 months, whereas 50:50 compositions exhibit fastest hydrolysis (2-4 weeks) due to maximized amorphous content13. The molecular weight critically determines initial strength and degradation timeline: high molecular weight PLLA (Mw 200,000-300,000 Da) maintains tensile strength above 80% for 4-6 weeks in vivo, while lower molecular weight variants (Mw 50,000-100,000 Da) lose 50% strength within 2-3 weeks1218.

The hydrolytic degradation mechanism proceeds via random ester bond cleavage, generating lactic acid monomers that enter the Krebs cycle for metabolic clearance10. Degradation kinetics follow pseudo-first-order kinetics with rate constants influenced by crystallinity (slower in crystalline regions), pH (accelerated in acidic environments), and implant geometry (surface erosion dominates in thin fibers)9. Complete mass loss occurs within 12-24 months for PLLA sutures, compared to 3-6 months for PLGA variants615.

Manufacturing Processes And Fiber Engineering For Polylactic Acid Sutures

Melt-Extrusion And Drawing Techniques

Conventional polylactic acid suture production employs melt-extrusion at 180-220°C followed by multi-stage drawing to achieve target diameter and mechanical properties18. The extrusion process involves feeding polylactic acid pellets (average particle size 1-5 mm, intrinsic viscosity 1-5 dL/g) through heated barrels where shear forces induce molecular alignment12. Drawing ratios of 4:1 to 8:1 enhance tensile strength by 40-60% through strain-induced crystallization and fibrillar orientation along the fiber axis9. Monofilament sutures (USP sizes 2-0 to 6-0) are produced via single-pass extrusion, while multifilament constructions require braiding of 6-12 individual filaments to balance strength and flexibility6.

Critical process parameters include:

• Extrusion temperature: 190-210°C for PLLA, 170-190°C for PLGA to prevent thermal degradation18
• Drawing temperature: 60-80°C (above Tg) to enable molecular mobility without melting9
• Cooling rate: Rapid quenching (>50°C/min) produces amorphous fibers, while controlled cooling (5-10°C/min) maximizes crystallinity12

Electrospinning For Nanofiber Suture Architectures

Electrospinning enables fabrication of ultra-thin polylactic acid nanofiber sutures (diameter 200-800 nm) with enhanced surface area for drug loading and cellular interaction38. The process applies high voltage (15-25 kV) to polymer solutions (8-12 wt% polylactic acid in chloroform/DMF mixtures) to generate charged jets that solidify into nanofibers upon solvent evaporation8. Twisting bundles of aligned nanofibers into multifilament sutures (10-50 fibers per bundle) produces constructions meeting USP specifications for ophthalmic applications (breaking strength >0.18 N for 10-0 sutures)38.

Electrospun polylactic acid sutures demonstrate superior mechanical properties compared to conventional monofilaments: tensile strength reaches 120-150 MPa due to molecular confinement effects in nanoscale fibers, representing 80-100% improvement over melt-extruded equivalents8. The high surface-to-volume ratio (50-80 m²/g) facilitates incorporation of therapeutic agents at loadings up to 15 wt% without compromising structural integrity3. Polycaprolactone (PCL) is frequently blended with polylactic acid in electrospinning formulations to enhance flexibility and slow degradation, with PCL:PLA ratios of 30:70 to 50:50 providing optimal balance8.

Surface Modification And Coating Technologies

Surface coatings address handling deficiencies of uncoated polylactic acid sutures, particularly stiffness and high friction coefficients (μ = 0.35-0.45)511. Coating formulations comprise:

• Calcium stearate-based coatings: Blends of ε-caprolactone homopolymer or copolymer with 2-8 wt% calcium stearate reduce friction coefficient to 0.15-0.20 and improve knot strength by 10-50%1113. The coating is applied via dip-coating in organic solvents (dichloromethane or acetone) at 0.5-2.0 wt% solid content, followed by drying at 40-50°C14.

• Polyethylene glycol (PEG) coatings: PEG (Mw 400-4000 Da) blended with polylactic acid or polyglycolic acid oligomers provides lubricity while maintaining absorbability5. The thermoplastic coating is applied at 60-80°C and solidifies upon cooling, with thickness controlled at 2-5 μm to preserve suture diameter tolerances5.

• Hyaluronic acid incorporation: Hyaluronic acid (0.1-5.0 wt%) distributed within polylactic acid matrix or coated on surfaces imparts moisturizing effects and enhances tissue integration615. Manufacturing involves blending hyaluronic acid sodium salt (Mw 800,000-1,200,000 Da) with polylactic acid during extrusion or applying aqueous hyaluronic acid solutions (1-3 wt%) post-fabrication15.

Antimicrobial coatings incorporating silver nanoparticles (10-50 nm, 0.1-1.0 wt%), grapefruit extract (naringin 0.5-2.0 wt%), or antibiotics (levofloxacin, metronidazole at 5-15 wt%) prevent surgical site infections131416. Therapeutic deep eutectic solvent (THEDES) technology enables drug loadings exceeding 30 wt% by forming eutectic mixtures of maleic acid and antibiotics that plasticize the polylactic acid matrix without phase separation416.

Mechanical Performance And Degradation Kinetics Of Polylactic Acid Sutures

Tensile Properties And Knot Security

Polylactic acid sutures must satisfy USP specifications for tensile strength and knot strength across size ranges. For USP 2-0 sutures (diameter 0.30-0.339 mm), minimum straight tensile strength is 2.22 N and knot strength is 1.78 N3. High molecular weight PLLA sutures (Mw >200,000 Da) achieve initial tensile strengths of 60-80 MPa, translating to breaking loads of 3.5-5.0 N for 2-0 sizes, providing 60-125% safety margin above specifications912.

Knot security depends on friction characteristics and fiber stiffness. Uncoated polylactic acid monofilaments exhibit knot slippage under cyclic loading due to low surface friction, requiring 5-7 throws for secure knots compared to 3-4 throws for coated variants11. Calcium stearate coatings increase knot-pull breaking strength by 15-40% through enhanced inter-fiber friction while maintaining knot run-down smoothness1113. Multifilament braided constructions provide superior knot security (knot efficiency 75-85%) compared to monofilaments (60-70%) due to increased surface contact area6.

In Vivo Strength Retention Profiles

Polylactic acid sutures maintain functional strength during the critical wound healing period (14-21 days for skin, 28-42 days for fascia) before undergoing accelerated degradation910. Strength retention profiles vary by composition:

• PLLA sutures: Retain >80% initial strength at 4 weeks, 60-70% at 8 weeks, and 40-50% at 12 weeks, with complete absorption by 18-24 months915
• PLGA (90:10) sutures: Maintain 70-80% strength at 2 weeks, 40-50% at 4 weeks, with full degradation by 3-4 months613
• PLGA (50:50) sutures: Rapid strength loss to 50% by 2 weeks and 20% by 4 weeks, suitable for rapidly healing tissues, complete absorption in 8-12 weeks13

Thermal steam treatment accelerates degradation kinetics while preserving initial mechanical properties, enabling customization of absorption profiles9. Steam exposure at 120-130°C for 15-30 minutes increases hydrophilicity and introduces micro-cracks that facilitate water penetration, reducing time to 50% strength loss by 20-30% without compromising initial knot strength9.

Biocompatibility And Tissue Response

Polylactic acid sutures elicit minimal foreign body reaction, with inflammatory responses resolving within 7-14 days post-implantation1015. Histological studies demonstrate thin fibrous capsule formation (thickness 20-40 μm) around PLLA sutures at 4 weeks, comparable to non-absorbable nylon controls8. The degradation products (lactic acid) are metabolized via the citric acid cycle, preventing local acidification that could impair healing10.

Hyaluronic acid-containing polylactic acid sutures enhance tissue integration by promoting fibroblast migration and collagen synthesis615. In vivo studies show 25-35% increase in collagen deposition within 5 mm of suture tracks compared to unmodified controls at 3 weeks post-implantation15. The sustained release of hyaluronic acid (0.5-1.5 μg/day over 4-6 weeks) maintains tissue hydration and reduces scar formation15.

Drug-Eluting Polylactic Acid Sutures For Infection Prevention And Therapeutic Delivery

Antibiotic-Loaded Suture Systems

Surgical site infections (SSIs) occur in 2-5% of clean surgical procedures and up to 40% in contaminated abdominal surgeries, driving development of antimicrobial sutures16. Polylactic acid serves as an ideal matrix for antibiotic delivery due to its biodegradability and processing compatibility with heat-sensitive drugs3416.

Electrospun polylactic acid/PCL nanofiber sutures loaded with levofloxacin (5-15 wt%) deliver therapeutic concentrations (>2 μg/mL) in ocular tissues for 14-30 days, preventing infection against Staphylococcus aureus and Pseudomonas aeruginosa challenges38. The multifilament architecture (twisted bundles of 20-40 nanofibers) maintains breaking strength above USP specifications despite drug incorporation, unlike monofilament electrospun sutures which lose >50% strength with equivalent loadings8. Release kinetics follow biphasic profiles: initial burst release (20-30% in first 24 hours) from surface-associated drug, followed by sustained release (0.5-2.0 μg/day) from matrix-encapsulated reservoirs over 3-4 weeks3.

THEDES-based formulations achieve antibiotic loadings up to 35 wt% by forming eutectic mixtures of metronidazole with maleic acid (molar ratio 1:1 to 1:2) that remain miscible with polycaprolactone or PLGA matrices during extrusion416. These sutures reduce SSI incidence by 60-75% in contaminated wound models compared to uncoated controls, with antimicrobial efficacy maintained for 7-10 days16.

Anti-Inflammatory And Analgesic Suture Coatings

Post-operative inflammation and pain management benefit from localized drug delivery via suture coatings. Dexamethasone-loaded polylactic acid sutures (drug loading 3-8 wt%) release 10-50 μg/day for 7-14 days, reducing inflammatory cell infiltration by 40-55% and pain scores by 30-45% in ophthalmic surgery models38. The hydrophobic nature of polylactic acid enables sustained release of lipophilic anti-inflammatory agents (triamcinolone, flurbiprofen) with near-zero-order kinetics over 2-4 weeks3.

Grapefruit extract containing naringin (0.5-2.0 wt%) incorporated into PLGA suture coatings provides dual antimicrobial and anti-inflammatory effects13. Naringin inhibits bacterial adhesion (50-70% reduction in Staphylococcus epidermidis colonization) while suppressing pro-inflammatory cytokine expression (IL-6, TNF-α reduced by 35-50%) without the toxicity concerns of metallic antimicrobials13.

Applications Of Polylactic Acid Sutures Across Surgical Specialties

Ophthalmic Surgery Applications

Polylactic acid sutures dominate ophthalmic applications due to their ultra-fine diameters (USP 8-0 to 11-0, diameter 0.04-0.10 mm) and predictable absorption eliminating removal procedures that risk corneal damage3810. Electrospun polylactic acid/PCL multifilament sutures meet stringent ophthalmic requirements: breaking strength >0.18 N for 10-0 size, knot strength >0.14 N, and diameter uniformity within ±5%38. The nanofiber architecture provides flexibility (bending modulus 0.8-1.2 GPa) enabling atraumatic passage through delicate tissues while maintaining structural integrity during knot tying8.

Antibiotic-eluting polylactic acid sutures prevent endophthalmitis, a devastating complication occurring in 0.05-0.3% of cataract surgeries3. Levofloxacin-loaded sutures (10 wt% drug loading) maintain intraocular antibiotic concentrations above minimum inhibitory concentration (MIC) for common pathogens (Staphylococcus aureus MIC 0.5 μg/mL, Pseudomonas aeruginosa MIC 1.0 μg/mL) for 20-30 days, compared to 6-8 hours for topical drops38. Clinical studies demonstrate 85-90% reduction in post-operative infection rates with drug-eluting sutures versus conventional prophylaxis8.